Forsight Vision 5 company presentation from OIS@AAO 2015

1. Proprietary & Confidential © ForSight VISION5 2015
Ophthalmology Innovation Summit @ AAO
November 2015

2. Proprietary © ForSight VISION5 2015 2
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Non-Adherence:
The Great Frontier of Ophthalmology
1Nordstrom, et al. AJO 2005;140:598-606.; 2Hennessy AL, et al. AJO. 2011 Dec;152(6):982-8
 <50% of Patients Use Their Drops1
 ~60% Cannot Administer Drops2
 Durable Effect
 Non-invasive, Retained
 Simple, In-Office Placement
Solution: V5 Sustained Release Ring
Great Frontier
$2B Market
Everyone Loses: Patients, Physicians,
Drop Providers

3. Proprietary © ForSight VISION5 2015 3
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Consistent Performance in Clinical Trials:
Four Phase 1 (N=73) & Four Phase 2 (N=251)
 Topical, Comfortable (90%),
Well-retained (90% at 6 months)1
Durable Efficacy
 One ring provides clinically significant
IOP reduction for 6 months2
Safety & Benefits
 Uneventful safety profile
 Regulatory pathway: NDA in 2019
Patient Acceptance
Market Value
 85% of patients recommend insert3
 80% of doctors prefer insert to drops4
Future
 Validated Platform for Fixed Combination
Glaucoma, Allergy, Dry Eye, Other Pipeline
1FSV5-002, 2Goldberg et al. WGC 2015; 3Study 20150706; 4GLG Survey

4. Proprietary © ForSight VISION5 2015 4
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Patient Acceptance:
Simple, Comfortable, Well-Retained
Filmed at the Sall Research Medical Center; Artesia, CA
 90% of Patients are Comfortable Wearing Non-medicated Ring1
 90% of Patients Retain Inserts (OU) for 6 Months2
1Study 305, FSV5-002 & FSV5-004 (washout); 1FSV5-002

5. Proprietary © ForSight VISION5 2015 5
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Phase 1 Efficacy Results1
Mean Diurnal Intraocular Pressure (IOP)
with Bimatoprost Insert (N = 27 subjects)
 Mean IOP reduction: 4.7 to 6.5 mmHg from washout
1Goldberg, I. et al. (2015, June). Poster presented at World Glaucoma Congress 2015.
5.1
mmHg

6. Proprietary © ForSight VISION5 2015 6
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Phase 2:
Two Efficacy Studies with Open-Label Extension Studies
 Data will be presented by Dr. James Brandt on Tuesday @ 9:03 am
(Venetian D)
 Bimatoprost Insert demonstrated clinically significant IOP-Lowering for 6 Months1
 ~90% of subjects had unassisted retention of inserts through 6 months
 Safety was uneventful and consistent with earlier data
 Second Phase 2 Study FSV5-004: Dose-Ranging: Full Data in Q4:15
Screening
N=169
Randomized
(1:1)
N=130
PGA
Insert
+
Artificial Tears
Placebo
Insert
+
0.5% Timolol
6 months
6 months
 First Phase 2 Study: FSV5-002
1Presentation abstract: mean diurnal IOP; available on AAO website

7. Proprietary © ForSight VISION5 2015 7
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Regulatory Pathway Identified
 Pathway Identified; NDA Filing In 2019
 FDA Guidance On Approach
 Precedent For Products With Similar Efficacy-Safety Profile
Regulatory
Pathway
Durable
Efficacy
Safety

8. Proprietary © ForSight VISION5 2015 8
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Voice of Customer: Patients Recommend Insert
1Study 20150706 (N=92)
55%
30%
11%
1% 1% 1%
Strongly
Agree
Agree Neutral Disagree Strongly
Disagree
No Response
• 85% of Our Patients Would
Recommend Product to Friend
or Family with Adherence
Challenges1
85%

9. Proprietary © ForSight VISION5 2015 9
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Voice of Customer: Physicians Prefer Insert
1GLG Survey, Q45.; 2Leerink Survey, Q13; S2N Market Research Survey, M3 Market Research Data
83%
10% 8%
Prefer Insert to Drops Insert ≈ Drops Prefer Drops to Insert
 >80% of Physicians Prefer Helios
Product Profile to PGA Eye
Drop1
 When available, expect to use
in >50% of Glaucoma Patients2

10. Proprietary © ForSight VISION5 2015 10
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Imagine a Future without Drops…
Proprietary, Validated Platform Continues to Deliver Opportunity
Life Cycle Management: Generic & Proprietary Compounds
The Future is Here Today for Glaucoma
Glaucoma
Fixed-Combo
Glaucoma
Allergy
Dry Eye

11. Proprietary © ForSight VISION5 2015 11
The Helios InsertTM is limited by United States Law to Investigational Use Only.
Investment Highlights
 Innovative company developing non-invasive sustained therapy
for major eye diseases
 First product candidate (HeliosTM Insert) expected to start Phase 3
in 2016.
– Significant opportunity to address unmet adherence need in
$6+ billion1 WW glaucoma market
 Ocular insert validated as delivery system:
– Applications to dry eye, allergy, research collaborations
 Blue Chip Investors:
1Estimates from Allergan investor presentation, 30 Jun 2014.